Page
%P
-
Article
Prognostic and predictive factors and genetic analysis of early breast cancer
The great heterogeneity of breast cancer makes it impossible to firmly predict which patients with early-stage tumours will or will not need systemic treatments according to the conventional prognostic factors...
-
Article
Open AccessMethylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivotumor growth
Melanoma is the most deadly form of skin cancer without effective treatment. Methylthioadenosine (MTA) is a naturally occurring nucleoside with differential effects on normal and transformed cells. MTA has bee...
-
Article
Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain
Our aim was to evaluate the cost-effectiveness of docetaxel versus weekly paclitaxel regimen in patients with metastatic breast cancer previously treated with anthracycline from the Spanish National Health Ser...
-
Article
Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma
The aim of this study was to analyze the outcome of patients undergoing hepatic resection for melanoma liver metastases.
-
Article
HER2 and hormone receptor-positive breast cancer—blocking the right target
Chemotherapy and trastuzumab is standard therapy for HER2-positive breast cancer, although aromatase inhibitors combined with anti-HER2 therapies is an option in patients with HER2 and hormone receptor-positiv...
-
Article
Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?
The current understanding of the molecular biology of breast cancer presents an extremely complex portrait of the disease. Based on this knowledge, considerable efforts are being made to identify biomarkers th...
-
Book
-
Chapter
HER2-Positive Metastatic Breast Cancer: First-Line Treatment
Prognoses for patients with breast cancer overexpressing the human epidermal growth factor receptor 2 (HER2) have markedly improved with the administration of anti-HER2-targeted therapy.
-
Article
Open AccessExposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters
The phase III trial of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel for first-line treatment of HER2-positive metastatic breast cancer included a substudy to determ...
-
Article
Open AccessGenomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity
To improve our understanding of the biological relationships among different types of cancer, we have characterized variation in gene expression patterns in a set of 1,707 samples representing 6 human cancer t...
-
Article
Open AccessEvaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study
Molecular markers that predict responses to particular therapies are invaluable for optimization of patient treatment. The TRYPHAENA study showed that pertuzumab and trastuzumab with chemotherapy was an effica...
-
Article
Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors
To characterize the population pharmacokinetics (PK) of pertuzumab across clinical trials in a variety of solid tumors, evaluate the potential impact of patient characteristics on PK, and confirm the appropri...
-
Article
Open AccessRationale for targeting fibroblast growth factor receptor signaling in breast cancer
Fibroblast growth factor receptor (FGFR) signaling is involved in multiple biological processes, including cell proliferation, survival, differentiation, migration, and apoptosis during embryonic development a...
-
Article
Erratum: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity
To improve our understanding of the biological relationships among different types of cancer, we have characterized variation in gene expression patterns in a set of 1,707 samples representing 6 human cancer t...
-
Book
-
Chapter
HER2-positive metastatic breast cancer: first-line treatment
Prognoses for patients with breast cancer overexpressing the human epidermal growth factor receptor 2 (HER2) have markedly improved with the administration of anti-HER2-targeted therapy. In the last decade, tr...
-
Article
Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
Brain metastases are a major cause of morbidity and mortality for women with hormone receptor (HR)-positive breast cancer, yet little is known about the optimal treatment of brain disease in this group of pati...
-
Article
Open AccessSafety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial
New treatments with novel mechanisms of action and non-overlap** toxicities are needed for patients with metastatic breast cancer. Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor with a un...
-
Article
Translating neoadjuvant therapy into survival benefits: one size does not fit all
Neoadjuvant therapy is the standard of care for patients with locally advanced breast cancer and can improve operability of breast cancer
-
Article
Open AccessBeneficial effects of a Coriolus versicolor-based vaginal gel on cervical epithelization, vaginal microbiota and vaginal health: a pilot study in asymptomatic women
To assess the effect of a 12-day treatment using a vaginal gel based on niosomes containing hyaluronic acid, ß-glucan, alpha-glucan oligosaccharide, Coriolus versicolor, Asian centella, Azadirachta indica and Alo...
